Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Endoscopic full-thickness resection of a long intussuscepted appendix by use of a colonoscope.

Hammoud GM, Quick J, Samiullah S, Rao D, Ibdah JA.

VideoGIE. 2018 Nov 23;4(1):34-36. doi: 10.1016/j.vgie.2018.10.001. eCollection 2019 Jan. No abstract available.

2.

Removal of Esophageal Variceal Bands to Salvage Complete Esophageal Obstruction.

Jalil AAA, Hammoud G, Ibdah JA, Samiullah S.

Clin Endosc. 2018 Sep;51(5):491-494. doi: 10.5946/ce.2018.011. Epub 2018 Aug 21.

3.

Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders.

Heath RD, Cockerell C, Mankoo R, Ibdah JA, Tahan V.

North Clin Istanb. 2018 Feb 12;5(1):79-88. doi: 10.14744/nci.2017.10692. eCollection 2018. Review.

4.

Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice.

Nassir F, Arndt JJ, Johnson SA, Ibdah JA.

J Lipid Res. 2018 Jun;59(6):967-973. doi: 10.1194/jlr.M080952. Epub 2018 Mar 26.

5.

Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy.

Natarajan SK, Ibdah JA.

Int J Mol Sci. 2018 Jan 22;19(1). pii: E322. doi: 10.3390/ijms19010322. Review.

6.

Hepatocyte transplantation: Consider infusion before incision.

Heath RD, Ertem F, Romana BS, Ibdah JA, Tahan V.

World J Transplant. 2017 Dec 24;7(6):317-323. doi: 10.5500/wjt.v7.i6.317. Review.

7.

Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - A randomized trial.

Winn NC, Liu Y, Rector RS, Parks EJ, Ibdah JA, Kanaley JA.

Metabolism. 2018 Jan;78:128-140. doi: 10.1016/j.metabol.2017.08.012. Epub 2017 Sep 20.

PMID:
28941598
8.

Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients.

Yousef MH, Al Juboori A, Albarrak AA, Ibdah JA, Tahan V.

World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):100-107. doi: 10.4291/wjgp.v8.i3.100. Review.

9.

Is the 25-year hepatitis C marathon coming to an end to declare victory?

Ahmed KT, Almashhrawi AA, Ibdah JA, Tahan V.

World J Hepatol. 2017 Jul 28;9(21):921-929. doi: 10.4254/wjh.v9.i21.921. Review.

10.

Coffee: The magical bean for liver diseases.

Heath RD, Brahmbhatt M, Tahan AC, Ibdah JA, Tahan V.

World J Hepatol. 2017 May 28;9(15):689-696. doi: 10.4254/wjh.v9.i15.689. Review.

11.

Synchronous Gastrointestinal Carcinoid Tumor and Colon Adenocarcinoma: Case Reports and Literature Review.

Winn JN, Sathyamurthy A, Kneib JL, Ibdah JA, Tahan V.

Am J Case Rep. 2017 Jun 6;18:626-630. Review.

12.

Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study.

Rahman R, Simoes EJ, Schmaltz C, Jackson CS, Ibdah JA.

Cancer Med. 2017 Apr;6(4):874-880. doi: 10.1002/cam4.1044. Epub 2017 Mar 20.

13.

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.

Mir F, Kahveci AS, Ibdah JA, Tahan V.

Drug Des Devel Ther. 2017 Feb 23;11:497-502. doi: 10.2147/DDDT.S130945. eCollection 2017. Review.

14.

Undigested Pills in Stool Mimicking Parasitic Infection.

Mir F, Achakzai I, Ibdah JA, Tahan V.

Case Rep Gastrointest Med. 2017;2017:3718954. doi: 10.1155/2017/3718954. Epub 2017 Jan 31.

15.
16.

Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma.

Khare T, Khare S, Ibdah JA.

World J Gastrointest Oncol. 2017 Jan 15;9(1):1-3. doi: 10.4251/wjgo.v9.i1.1.

17.

Corrigendum: 2016 ACG Abstracts- Outcomes Research.

Bechtold ML, Asombang A, Madsen R, Simuyandi M, Phiri G, Ibdah JA, Lishimpi K, Banda L.

Am J Gastroenterol. 2017 Jul;112(7):1208-1209. doi: 10.1038/ajg.2016.588. Epub 2017 Jan 10.

PMID:
28071658
18.

Sirtuins and nonalcoholic fatty liver disease.

Nassir F, Ibdah JA.

World J Gastroenterol. 2016 Dec 14;22(46):10084-10092. doi: 10.3748/wjg.v22.i46.10084. Review.

19.

Microbiome alterations observed in liver diseases present opportunities for potential fecal transplantation.

Heath RD, Mir F, Ibdah JA, Tahan V.

Turk J Gastroenterol. 2016 Nov;27(6):495-498. doi: 10.5152/tjg.2016.160011. Review.

20.

Aerobic capacity and hepatic mitochondrial lipid oxidation alters susceptibility for chronic high-fat diet-induced hepatic steatosis.

Morris EM, Meers GM, Koch LG, Britton SL, Fletcher JA, Fu X, Shankar K, Burgess SC, Ibdah JA, Rector RS, Thyfault JP.

Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E749-E760. doi: 10.1152/ajpendo.00178.2016. Epub 2016 Sep 6.

Supplemental Content

Loading ...
Support Center